Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries.
Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries. Experts suggest the value of DCTs will increase by 9.8% between 2023 to 2029. Decentralized Clinical trials are cost effective and offer many benefits to researchers and participants alike, which is likely the cause of their increased usage. However, there are also some risks involved. To address this, the FDA released draft guidance to regulate DCTs and ensure participant privacy and data is protected. The guidance covers data collection and storage, investigator and sponsor responsibilities, and more.
DISCOVER MORE
![](https://fdaqrc.com/wp-content/uploads/2024/09/portfolio38-370x484.jpg)
How To Find Qualified Patients for Your Clinical Trials
Streamline patient recruitment and match participants to your specific research criteria with Quri.AI’s advanced AI-driven solutions. Save time, reduce costs, and enhance the success of your clinical trials.
![](https://fdaqrc.com/wp-content/uploads/2024/07/portfolio37-370x484.jpg)
Simplified Standard Operating Procedures Can Reduce FDA Citations and Enhance Compliance Culture
Failure to fully adhere to Standard Operating Procedures (SOPs) is a leading cause of FDA warning letters, with over half of the citations issued annually addressing this concern.
![](https://fdaqrc.com/wp-content/uploads/2024/05/portfolio36-370x484.webp)
Creating a Supportive Workplace: Recognizing and Addressing Mental Health
Fostering well-being in the workplace involves raising awareness and encouraging self-care. Implementing strategies to prevent burnout and support mental health is essential for a positive, inclusive environment..
![](https://fdaqrc.com/wp-content/uploads/2024/05/portfolio35-370x484.webp)
AI in Clinical Trials: Transforming Research and Regulation
Exploring AI's Role in Streamlining Clinical Trials, Addressing Regulatory Complexity, and Balancing Ethical Considerations
![](https://fdaqrc.com/wp-content/uploads/2024/03/portfolio34-370x484.webp)
FDAQRC's Retreat and Reconnect
Our team experienced the wonders of Costa Rica while strengthening team bonds and making memories at the 2024 Face-2-Face annual meeting.
![](https://fdaqrc.com/wp-content/uploads/2024/02/portfolio35-370x484.webp)
Pharmacovigilance: Insights, Challenges, and Future Horizons
Navigating drug safety with a focus on insights, challenges, and digital innovations for a safer future.
![Employees celebrating](https://fdaqrc.com/wp-content/uploads/2024/01/portfolio34-370x484.webp)
The Future Looks Bright
Unveiling a year of achievements, growth, and industry connections - FDAQRC sets the stage for a thriving future in 2024.
![Aggie 100](https://fdaqrc.com/wp-content/uploads/2024/01/portfolio33-370x484.webp)
FDAQRC Named a 2024 Aggie 100 Honoree
FDAQRC is among the top 100 companies globally selected for the 19th annual Aggie 100 which honors the fastest-growing companies owned or led by Texas A&M Alum.